WallStreetZenWallStreetZen

NASDAQ: TRVI
Trevi Therapeutics Inc Stock Ownership - Who owns Trevi Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Trevi Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Thomas SciasciaChief Scientific Officer2025-03-252,631$6.60
$17.36kSell
Thomas SciasciaChief Scientific Officer2025-03-252,631$1.43
$3.76kBuy
Jennifer L. GoodPresident CEO2025-03-215,263$6.58
$34.63kSell
Jennifer L. GoodPresident CEO2025-03-215,263$1.43
$7.53kBuy
Farrell SimonChief Commercial Officer2025-03-104,350$7.15
$31.10kSell
Farrell SimonChief Commercial Officer2025-03-1063,813$3.91
$249.51kBuy
Farrell SimonChief Commercial Officer2025-03-1031,250$0.51
$15.97kBuy
Farrell SimonChief Commercial Officer2025-03-1076,963$6.73
$517.81kSell
Farrell SimonChief Commercial Officer2025-03-1017,500$3.21
$56.18kBuy
Lisa DelfiniChief Financial Officer2025-01-085,000$0.51
$2.56kBuy

1 of 2

TRVI insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRVI insiders and whales buy or sell their stock.

TRVI Shareholders

What type of owners hold Trevi Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Scott D. Sandell14.21%17,308,374$176.37MInsider
Mohamad Makhzoumi14.21%17,308,374$176.37MInsider
Ali Behbahani14.21%17,308,374$176.37MInsider
Peter W. Sonsini14.21%17,308,374$176.37MInsider
Paul Edward Walker14.21%17,308,374$176.37MInsider
Anthony A. Florence Jr.14.21%17,308,374$176.37MInsider
Carmen Chang14.21%17,308,374$176.37MInsider
Forest Baskett13.43%16,359,426$166.70MInsider
Nea Management Company LLC10.86%13,222,228$134.73MInstitution
New Enterprise Associates 16 LP8.56%10,421,428$106.19MInsider

1 of 3

TRVI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRVI38.52%61.48%Net Buying
SNDX91.99%8.01%Net BuyingNet Buying
ZYME53.28%46.72%Net BuyingNet Buying
WVE68.10%31.90%Net BuyingNet Selling
ELVN49.49%50.51%Net SellingNet Selling
View Top Biotech Stocks

Trevi Therapeutics Stock Ownership FAQ

Who owns Trevi Therapeutics?

Trevi Therapeutics (NASDAQ: TRVI) is owned by 94.15% institutional shareholders, 150.26% Trevi Therapeutics insiders, and 0.00% retail investors. Scott D. Sandell is the largest individual Trevi Therapeutics shareholder, owning 17.31M shares representing 14.21% of the company. Scott D. Sandell's Trevi Therapeutics shares are currently valued at $183.81M.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.